AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12975676 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) combined with clozapine
Number of subjects: 0
Study 12975676 — intervention group
Group type: COMPARATOR
Intervention: Clozapine alone
Number of subjects: 0
Study 10755397 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH‐P treatment administered just after diagnosis (4 days every 6 weeks)
Number of subjects: 145
Study 10755397 — intervention group
Group type: COMPARATOR
Intervention: Treatment at disease progression
Number of subjects: 145
Study 10755397 — intervention group
Group type: COMPARATOR
Intervention: Patients treated at disease progression
Number of subjects: 145
Study 8874688 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician nutrition counseling training plus a structured office practice environment for nutrition management (prompts and the provision of lipid results and counseling algorithms)
Number of subjects: 1278
Study 8874688 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician nutrition counseling training
Number of subjects: 1278
Study 8874688 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1278
Study 1608258 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Auditory Attention Test (SAAT)
Number of subjects: 40
Study 6366100 — intervention group
Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/day
Number of subjects: 39
Study 6366100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30072263 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin
Number of subjects: 40
Study 30072263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29885165 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-tubal local anaesthetic infiltration of 0.25% bupivacaine
Number of subjects: 68
Study 29885165 — intervention group
Group type: COMPARATOR
Intervention: 10ml 0.9% normal saline infiltration
Number of subjects: 68
Study 28325013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy combined with Electrical Stimulation (ES)
Number of subjects: 18
Study 28325013 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 18
Study 25219290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients with peripheral vertigo
Number of subjects: 103
Study 25219290 — intervention group
Group type: COMPARATOR
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in healthy controls
Number of subjects: 103
Study 22507360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk intervention using psychologically informed practice
Number of subjects: 0
Study 22507360 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and targeted approach
Number of subjects: 0
Study 22507360 — intervention group
Group type: COMPARATOR
Intervention: Current best practice
Number of subjects: 0
Study 20211180 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers
Number of subjects: 598
Study 18174491 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 8832
Study 16149365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 28
Study 16149365 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 28
Study 11880102 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase gene 3'-UTR T/C polymorphism
Number of subjects: 153
Study 11880102 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 153
Study 10520842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyoscyamine (0.25 mg)
Number of subjects: 165
Study 10520842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hyoscyamine (0.25 mg)
Number of subjects: 165
Study 10520842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 7741341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.1 gm/kg)
Number of subjects: 20
Study 7741341 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of water added to nonalcoholic beer)
Number of subjects: 20
Study 2037704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16
Study 2037704 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study 6290927 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4-9 Analogue (ORG 2766)
Number of subjects: 4
Study 31839558 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment plus usual care (CPAP group)
Number of subjects: 2551
Study 31839558 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (UC group)
Number of subjects: 2551
Study 31839558 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no OSA)
Number of subjects: 2551
Study 31409522 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 521
Study 31409522 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 521
Study 28701501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (systolic BP <140 mm Hg)
Number of subjects: 989
Study 28701501 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment (systolic BP <180 mm Hg)
Number of subjects: 989
Study 28701501 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT markers (intrahematoma hypodensities, black hole sign, swirl sign, blend sign, heterogeneous hematoma density, irregular shape)
Number of subjects: 989
Study 25526517 — intervention group
Group type: EXPERIMENTAL
Intervention: HDHK program (7 sessions)
Number of subjects: 122
Study 24420550 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 60
Study 24420550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 21182510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc pyrithione (ZPT) shampoo, treated for 3 weeks
Number of subjects: 0
Study 21182510 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated product, treated for 3 weeks
Number of subjects: 0
Study 19610263 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient cream with furfuryl palmitate
Number of subjects: 117
Study 19610263 — intervention group
Group type: COMPARATOR
Intervention: Basic emollient cream
Number of subjects: 117
Study 17563160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 156
Study 17563160 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation‐phase cognitive therapy
Number of subjects: 156
Study 15964328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal and epidural anesthesia
Number of subjects: 50
Study 15964328 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 11847621 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-substituting TKA
Number of subjects: 47
Study 11847621 — intervention group
Group type: COMPARATOR
Intervention: PCL-retaining TKA
Number of subjects: 47
Study 10076915 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 8963853 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.5% before and after ALT
Number of subjects: 471
Study 8963853 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.5% before ALT and vehicle after
Number of subjects: 471
Study 8963853 — intervention group
Group type: COMPARATOR
Intervention: Vehicle before and brimonidine 0.5% after
Number of subjects: 471
Study 8963853 — intervention group
Group type: COMPARATOR
Intervention: Vehicle before and after ALT
Number of subjects: 471
Study 2301911 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine block
Number of subjects: 50
Study 2301911 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine wound instillation
Number of subjects: 50
Study 6766244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 48
Study 6766244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31289062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasure&Pregnancy programme (web-based interactive educational programme) for 6 months
Number of subjects: 0
Study 31289062 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM) for 6 months
Number of subjects: 0
Study 31289062 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasure&Pregnancy programme
Number of subjects: 0
Study 31289062 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 0
Study 28430722 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine and bupivacaine injection
Number of subjects: 76
Study 28430722 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline injection)
Number of subjects: 76
Study 26010427 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 1)
Number of subjects: 32
Study 26010427 — intervention group
Group type: COMPARATOR
Intervention: Low doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 2)
Number of subjects: 32
Study 23700328 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training (5 times per week for 10 minutes over 6 weeks)
Number of subjects: 34
Study 23700328 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training
Number of subjects: 34
Study 22111518 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AER; running)
Number of subjects: 10
Study 22111518 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (RES; free and machine weights)
Number of subjects: 10
Study 22111518 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 19471031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telesonography
Number of subjects: 108
Study 19471031 — intervention group
Group type: COMPARATOR
Intervention: Control (ordinary ultrasound referral)
Number of subjects: 108
Study 17576587 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program
Number of subjects: 32
Study 17576587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 12697600 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming (set to 'medium')
Number of subjects: 24
Study 12697600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-fibre resistive warming (38 degrees C)
Number of subjects: 24
Study 12697600 — intervention group
Group type: COMPARATOR
Intervention: Circulating water mattress (38 degrees C)
Number of subjects: 24
Study 10715306 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,331 mg/m²/d bid continuously (arm A)
Number of subjects: 109
Study 10715306 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 2,510 mg/m²/d bid intermittently (2 weeks on/1 week off) (arm B)
Number of subjects: 109
Study 10715306 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1,657 mg/m²/d plus oral leucovorin 60 mg/d bid intermittently (2 weeks on/1 week off) (arm C)
Number of subjects: 109
Study 9374948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 20 mg once daily
Number of subjects: 187
Study 9374948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 1304283 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid (500 mg orally twice a day for the first 3 weeks) and carbimazole (30 mg orally in three divided doses)
Number of subjects: 30
Study 1304283 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole alone
Number of subjects: 30
Study 1304283 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid and carbimazole
Number of subjects: 30
Study 2932908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + Hydroxyurea (HU)
Number of subjects: 64
Study 2932908 — intervention group
Group type: COMPARATOR
Intervention: MOF-Strep (methyl-CCNU, oncovin, fluorouracil, and streptozotocin)
Number of subjects: 64
Study 31672939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 11
Study 31672939 — intervention group
Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 11
Study 30218416 — intervention group
Group type: EXPERIMENTAL
Intervention: L-praziquantel (PZQ) administered in two new oral dispersion tablet (ODT) formulations under various combinations of co-administration with food, water, and/or crushing.
Number of subjects: 0
Study 30218416 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for AUC extrapolated to children 2-5 years old accounting for enzyme maturation and weight.
Number of subjects: 0
Study 30218416 — intervention group
Group type: COMPARATOR
Intervention: Model used for healthy adult volunteers.
Number of subjects: 0
Study 30645842 — intervention group
Group type: EXPERIMENTAL
Intervention: Penning Granule (PG), 105 g each time, twice per day for 4 weeks
Number of subjects: 38
Study 30645842 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (0.5 g, once per day) and Metronidazole Tablet (0.5 g, twice daily for 1 week)
Number of subjects: 38
Study 30645842 — intervention group
Group type: EXPERIMENTAL
Intervention: Penning Granule (PG)
Number of subjects: 38
Study 25047312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (0.3 mg/kg)
Number of subjects: 60
Study 25047312 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.15 mg/kg)
Number of subjects: 60
Study 22496436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal rotationally asymmetric Lentis Mplus LS‐312 IOL with capsular tension ring
Number of subjects: 90
Study 22496436 — intervention group
Group type: COMPARATOR
Intervention: Multifocal rotationally asymmetric Lentis Mplus LS‐312 IOL without capsular tension ring
Number of subjects: 90
Study 20508466 — intervention group
Group type: EXPERIMENTAL
Intervention: weight+EMS (ES)
Number of subjects: 28
Study 20508466 — intervention group
Group type: EXPERIMENTAL
Intervention: weight (VOL)
Number of subjects: 28
Study 20508466 — intervention group
Group type: COMPARATOR
Intervention: control group (CG)
Number of subjects: 28
Study 18226581 — intervention group
Group type: COMPARATOR
Intervention: Six cycles of CHOP-14
Number of subjects: 1222
Study 18226581 — intervention group
Group type: COMPARATOR
Intervention: Eight cycles of CHOP-14
Number of subjects: 1222
Study 18226581 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of R-CHOP-14
Number of subjects: 1222
Study 18226581 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of R-CHOP-14
Number of subjects: 1222
Study 15976214 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (music group; n = 28)
Number of subjects: 54
Study 15976214 — intervention group
Group type: COMPARATOR
Intervention: No music (control group; n = 26)
Number of subjects: 54
Study 12583944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy (break in chemotherapy, re-starting on the same drug on progression)
Number of subjects: 354
Study 12583944 — intervention group
Group type: COMPARATOR
Intervention: Continuous chemotherapy (until progression)
Number of subjects: 354
Study 12583944 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 354
Study 10224577 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase-mediated fibrinolysis (group I, n = 8)
Number of subjects: 20
Study 10224577 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin by infusion (group II, n = 12)
Number of subjects: 20
Study 10224577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis after unsuccessful heparin treatment
Number of subjects: 20
Study 10224577 — intervention group
Group type: COMPARATOR
Intervention: Heparin treatment (unsuccessful case)
Number of subjects: 20
Study 8673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi antigens
Number of subjects: 30
Study 8673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella antigens
Number of subjects: 30
Study 8673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella antigens
Number of subjects: 30
Study 8673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yersinia antigens
Number of subjects: 30
Study 8673811 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy blood donors)
Number of subjects: 30
Study 1899455 — intervention group
Group type: EXPERIMENTAL
Intervention: Average dialysis treatment duration of less than 3.5 hours
Number of subjects: 600
Study 1899455 — intervention group
Group type: COMPARATOR
Intervention: Average dialysis treatment duration longer than 3.5 hours
Number of subjects: 600
Study 6848412 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium 111 leukocyte scan
Number of subjects: 15
Study 6848412 — intervention group
Group type: COMPARATOR
Intervention: Barium enema, colonoscopy, or surgery (control)
Number of subjects: 15
Study 31262599 — intervention group
Group type: EXPERIMENTAL
Intervention: High intra-abdominal pressure (IAP) during HIPEC (19 mmHg)
Number of subjects: 38
Study 31262599 — intervention group
Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (IAP) during HIPEC (11 mmHg)
Number of subjects: 38
Study 29415906 — intervention group
Group type: EXPERIMENTAL
Intervention: NKCP® (250 mg daily for 4 weeks)
Number of subjects: 30
Study 29415906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27112031 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radio-frequency ablation with ethanol injection (2.5-9.6 mL) and temperature control at 45-56 °C for more than 10 min.
Number of subjects: 141
Study 27112031 — intervention group
Group type: COMPARATOR
Intervention: Control group (ablation without ethanol injection, lesions more than 5 mm from gastrointestinal tract).
Number of subjects: 141
Study 27112031 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (percutaneous radio-frequency ablation).
Number of subjects: 141
Study 27112031 — intervention group
Group type: COMPARATOR
Intervention: Control group (percutaneous radio-frequency ablation).
Number of subjects: 141
Study 27112031 — intervention group
Group type: COMPARATOR
Intervention: Both groups (study and control).
Number of subjects: 141
Study 23823459 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot self-care educational intervention (3 sessions over 3 weeks)
Number of subjects: 70
Study 22452487 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA and UVB exposure
Number of subjects: 31
Study 22452487 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy skin phototypes (ESPTs) classification
Number of subjects: 31
Study 20445356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski helmet
Number of subjects: 30
Study 20445356 — intervention group
Group type: COMPARATOR
Intervention: Ski cap
Number of subjects: 30
Study 20445356 — intervention group
Group type: COMPARATOR
Intervention: Bareheaded
Number of subjects: 30
Study 18536337 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (90 min duration, 8 times over 3 months) including flexibility, resistance, and movement exercises.
Number of subjects: 88
Study 18536337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 88
Study 16047027 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation (15 g/day for 4 weeks after pneumococcal vaccine)
Number of subjects: 29
Study 16047027 — intervention group
Group type: COMPARATOR
Intervention: Control group (only the vaccine)
Number of subjects: 29
Study 12374442 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat primes (subliminal threat)
Number of subjects: 0
Study 12374442 — intervention group
Group type: COMPARATOR
Intervention: Neutral-word primes
Number of subjects: 0
Study 12374442 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment anxiety
Number of subjects: 0
Study 12374442 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment avoidance with threat prime 'separation'
Number of subjects: 0
Study 9915512 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic long‐throw guns (Acecut, Asap, Biopty, Magnum)
Number of subjects: 44
Study 9915512 — intervention group
Group type: COMPARATOR
Intervention: Conventional type side‐notch needle (Trucut), aspiration needle (Surecut), end‐cut needle (Autovac)
Number of subjects: 44
Study 9915512 — intervention group
Group type: COMPARATOR
Intervention: Short‐throw Monopty gun
Number of subjects: 44
Study 7479215 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 66
Study 7479215 — intervention group
Group type: COMPARATOR
Intervention: Non-dialysis treatment
Number of subjects: 66
Study 7479215 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 66
Study 2209300 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance weight training 3 days/wk for 10 wk
Number of subjects: 8
Study 6994939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH)
Number of subjects: 0
Study 6994939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6994939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) cessation
Number of subjects: 0
Study 31305297 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 45
Study 28297049 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal prednisolone
Number of subjects: 80
Study 28297049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25934853 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (50 mg, subcutaneous, once weekly for 24 weeks)
Number of subjects: 41
Study 25934853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to etanercept)
Number of subjects: 41
Study 25934853 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 41
Study 25934853 — intervention group
Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 41
Study 23636552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cost, home‐based physical activity and nutrition program
Number of subjects: 176
Study 21325445 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF followed by goserelin
Number of subjects: 1063
Study 21325445 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 1063
Study 21325445 — intervention group
Group type: COMPARATOR
Intervention: Goserelin
Number of subjects: 1063